APVO - Aptevo Therapeutics Inc.
6.4
-0.060 -0.937%
Share volume: 5,477
Last Updated: 03-06-2026
Pharmaceutical Products/Pharmaceutical Preparations:
3.14%
PREVIOUS CLOSE
CHG
CHG%
$6.46
-0.06
-0.01%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 06-30-2025 | 09-30-2025 | |
|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
| Report Date | 05-08-2024 | 08-08-2024 | 11-07-2024 | 02-14-2025 | 05-15-2025 | 08-11-2025 | 11-06-2025 | |
| Assets | ||||||||
| Total Assets | 17.629 M | 14.921 M | 15.146 M | 15.591 M | 8.342 M | 15.624 M | 26.996 M | |
| Current Assets | 12.074 M | 9.579 M | 10.012 M | 10.659 M | 3.607 M | 11.081 M | 22.649 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 691.000 K | 715.000 K | 624.000 K | 256.000 K | 120.000 K | 82.000 K | 77.000 K | |
| Short Term Investments | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Receivables | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current Cash | 10.250 M | 8.066 M | 7.753 M | 8.714 M | 2.139 M | 9.410 M | 21.061 M | |
| Total Non-current Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Property Plant Equipment | 789.000 K | 697.000 K | 614.000 K | 543.000 K | 482.000 K | 432.000 K | 384.000 K | |
| Other Assets | 4.766 M | 4.645 M | 4.520 M | 4.389 M | 4.253 M | 4.111 M | 3.963 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | ||||||||
| Total Liabilities and shareholders’ equity | 17.629 M | 14.921 M | 15.146 M | 15.591 M | 8.342 M | 15.624 M | 26.996 M | |
| Total liabilities | 11.526 M | 10.458 M | 10.726 M | 10.836 M | 9.815 M | 9.100 M | 9.604 M | |
| Total current liabilities | 6.298 M | 5.419 M | 5.882 M | 6.207 M | 5.393 M | 4.891 M | 5.614 M | |
| Accounts Payable | 3.720 M | 3.736 M | 3.532 M | 3.053 M | 3.789 M | 2.903 M | 2.219 M | |
| Other liabilities | 5.228 M | 5.039 M | 4.844 M | 4.629 M | 4.422 M | 4.209 M | 3.990 M | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 5.228 M | 5.039 M | 4.844 M | 4.629 M | 4.422 M | 4.209 M | 3.990 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 6.103 M | 4.463 M | 4.420 M | 4.755 M | -1.473 M | 6.524 M | 17.392 M | |
| Common stock | 236.384 M | 240.627 M | 245.685 M | 252.332 M | 252.512 M | 266.713 M | 286.609 M | |
| Retained earnings | -230.281 M | -236.164 M | -241.265 M | -247.577 M | -253.985 M | -260.189 M | -269.217 M |